Podcasts about mcla

This week, the Scions crew is joined by Georgia Tech Lacrosse head coach Ken Lovic to recap another fantastic season for the team after winning SELC's for the third consecutive year and making the MCLA national championship game against Liberty. Plus, some discussion on the inner workings of how the team operates within the current college recruiting landscape as a high functioning club team.The rest of the show:Baseball vs. #20 Louisville, Danny Hall's jersey retirementSoftball to the NCAA Tournament#25 Golf update after round 1 of the NCAA Regional in AuburnHosts: Jake Grant, Jack Purdy, Akshay EaswaranGuest: Ken LovicProduction: Jack PurdyMusic: ⁠⁠Georgia Tech⁠⁠ Glee Club, Georgia Tech Marching Band

Colter Nuanez examines the high stakes this season for Montana and Montana State football after spring ball wraps up. Plus: Jac Coyne of the MCLA joins Geoff Safford to preview the college club lacrosse national tournaments.

Episode 19: Erick Ramos-Jacobo Episode host Zurie Adams a recent graduate from Massachusetts College of Liberal Arts (MCLA), engages in a dynamic conversation with Erick: an MCLA alumni, curator, educator, and writer. In this episode, the pair discuss Erick's history with writing, image making, and photography, and how his artistic process has evolved. Eric also discusses how his work as a waiter has bolstered his work as a curator and artist, as well as his career goals going forward. A full transcript of the episode can be found here. THIS EPISODE'S VOICES: Eric Ramos-Jacobo is a writer, social practitioner and curator, who uses his work to educate and lift the voices of newcomer, or immigrant, communities in the Berkshires. As a student at Massachusetts College of Liberal Arts, Eric created The Mariposa Project, a collective of Newcomer artists collaborating to explore themes of cultural disorientation, place and identity experience by the community through creative channels of dialogue and community care.

What's it like to play at BYU? How did they go 19-0 and win their 6th national championship? Quint visited an early morning (6am) practice last week while in town to cover the BYU football game.

In this episode, Quint Kessenich catches up with Kyle Hartzell, Texas Longhorns MCLA head coach and former pro lacrosse player, to discuss his journey from player to coach. Kyle shares insights on the growing lacrosse scene in Texas, his recent hunting trip, and the challenges of balancing academics, athletics, and team culture. They also dive into the state of MCLA lacrosse, the importance of multi-sport athletes, and how Kyle's coaching approach is inspired by his own experiences as a professional player.

Welcome back to another episode of Crawfordsville Connection! This week, we spoke with Gina Haile and Monica Nagele to talk about the Montgomery County Leadership Academy's Day of Service. To learn more about the MCLA and to sign up for the Day of Service, click or tap here. To learn more about the United Way in Montgomery County, click or tap here. Yodel Community Calendar & News Feed, click or tap here. To ask any questions about this podcast or to submit topic ideas, please email Kurtis Broadstreet at kurtis.broadstreet@gmail.com.

Episode 18: Zurie Adams Episode host Erick Ramos-Jacobo, a recent graduate from Massachusetts College of Liberal Arts (MCLA), engages in a dynamic conversation with Zurie Adams: an MCLA alumna, theatre- and filmmaker. In this episode of Thinking Like a Region, they delve into Zurie's journey in the performing arts, her creative inspirations, and her aspirations for a future that intertwines various art forms. “Perfection is not real. The arts have taught me that because even with all of the rehearsals and every precaution, something is going to go wrong, and that is okay.” This episode emphasizes the importance of practical problem-solving, collaboration, and the influence of arts education on personal and professional development. You can find the transcript for this episode here: https://tinyurl.com/TLAW-ZA Thinking Like A Region is a production of the C4 Initiative, Berkshire County's Creative Compact for Collaborative and Collective Impact, based at Berkshire Regional Planning Commission in Pittsfield, MA, and grant-funded by the National Endowment for the Arts. This podcast is produced by Leslie Appleget and Lisa Donovan. For more information about the show or the C4 Initiative, visit brainworks.mcla.edu/c4. THIS EPISODE'S VOICES: Erick Ramos-Jacobo is an immigrant educator, curator, and social practitioner born in Zacatecas, Mexico. Renowned Brazilian Pop artist and Parque Lage professor, Bruno Miguel, noted him as “One of the most promising young curators” (Defining Moments, MASS MoCA, 2022). He's recognized for his work in the arts, particularly in collaboration with organizations like MASS MoCA, Barrington Stage Company, Assets 4 Artists at MASS MoCA, and Madison MoCA. Erick has had the privilege of working alongside curator and educator Dr. Laura Thompson on exhibitions and educational programs featuring notable artists such as Bruno Miguel, Shaun Leonardo, Anne Samat, and Federico Uribe. His passion lies in leveraging the power of the arts to build healthier, more vibrant, and equitable communities for immigrant individuals, with a special focus on museums as a starting point. Erick's curatorial work and educational development are currently on view at MASS MoCA and his newest collaboration, Metamorphosis|Metamorfosis, opened September 2023 at Madison MoCA.

Mike and Paul bring you a fresh new episode of One On Ones on the back of an incredible Week 6 in Fairfield, CT. The brothers recap the highlights from both field and sideline as well as answer your questions about the greatest draft class, MCLA, and how fatherhood. Have a questions for Mike and Paul? Leave a voicemail at 512-910-2218 Intro: (00:00) PLL Fairfield Recap: (04:54) PLL Rookies Into Superstars: (17:10) How MCLA Benefits Lacrosse: (22:04) A New Appreciate for Our Players: (27:34)

This week's show comes to you LIVE on-site from Boston Cannons homecoming weekend at Harvard Stadium. Mitch interviews serval players and personalities from around the lacrosse world and then the full cast recaps what was an exciting Week 5 as we head into the PLL All Star break. Intro: (00:00) Drip King: (00:32) Jack Rowlett: (11:30) RJ Kaminski: (30:00) LAXGUYSCOTTY: (40:13) Mitch's Mailbox: (49:58) PLL Week 5 Recap: (01:04:48) ASG Roster Reactions: (01:31:09) STX Athlete Signing: (01:49:10)

Dr. Diwakar Davar and Dr. Jason Luke discuss advances in the neoadjuvant immunotherapy space that were presented at the 2024 ASCO Annual Meeting, including promising outcomes in high-risk melanoma from the NADINA trial, as well as other new treatment options for patients with advanced cancers.    TRANSCRIPT Dr. Diwakar Davar: Hello and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar, and I am an associate professor of medicine and the clinical director of the Melanoma Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. I am delighted to have my colleague and friend Dr. Jason Luke on the podcast today to discuss key late-breaking abstracts and advances in immunotherapy that were presented at the 2024 ASCO Annual Meeting. Dr. Luke is an associate professor of medicine, the associate director of clinical research, and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center.   You will find our full disclosures in the transcript of this episode.  Jason, it's always a pleasure to hear your insights on the key trials in these spaces and to have you back as a guest on this podcast that highlights some of the work, especially advances, that were just presented. Dr. Jason Luke: Well, thanks very much for the invitation. I always love joining the podcast. Dr. Diwakar Davar: We'll start very quickly by talking about some advances and really interesting things that happened both in the context of melanoma but also in immunotherapy in general. And we'll start with what I think was certainly one highlight for me, which was LBA2, the late-breaking abstract on the NADINA trial. It was featured in the Plenary Session, and in this abstract, Dr. Christian Blank and colleagues reported on the results of this phase 3 trial of neoadjuvant ipi-nivo. This is the flipped dose of ipi1/nivo3 versus adjuvant nivolumab in PD-1 naive, macroscopic, resectable, high-risk stage 3 melanoma.  By way of background, neoadjuvant immunotherapy for those listening is an area of increasing interest for drug developers and development for both approved and novel agents. Neoadjuvant immunotherapy has been studied with multiple approved agents, including PD-1 monotherapy, PD-1 LAG-3, PD-1 CTLA-4, T-VEC, as well as investigational agents and multiple randomized and non-randomized studies. The benchmark pathologic response rates with these agents range from 17% PCR with PD-1 monotherapy, 45% to 55% PCR with PD-1 CTLA-4 combination therapy, and slightly higher 57% PCR with PD-1 LAG-3 has recently reported by Dr. Rodabe Amaria from MD Anderson. However, as we embark on phase 3 comparisons for various neoadjuvant compared to adjuvant immunotherapy trials and combinations, we're increasingly moving towards event-free survival as the primary endpoint for neoadjuvant versus adjuvant studies. And this was most recently studied in the context of SWOG S1801, a study that was led by Dr. Sapna Patel.  So, Jason, before we start on NADINA, can you briefly summarize the SWOG S1801 trial and the event-free survival statistic reported by Dr. Patel and her colleagues? Dr. Jason Luke: Well, absolutely. And these data were reported at ESMO about two years ago and then in the New England Journal last year. The S1801 study answered a very simple question: What would happen if you took three of the doses of standard adjuvant therapy with pembrolizumab and moved them prior to surgery? And on a high level, the study is as simple as that. And many of us were somewhat skeptical of this trial design because we thought that just moving the doses earlier may not actually have a major impact.  In the study, you alluded to the event-free survival statistic, and that alludes to what was considered an event. And so, without reading all of it, there were several different aspects that were included in terms of time, based on the date of randomization until the first of a series of events, such as disease progression, toxicity from treatment, if the patient was unable to go to surgery or had surgical complications, or if they had delay in starting the adjuvant therapy due to toxicity, and obviously, recurrence of melanoma or death from any cause. In that context, merely moving the 3 doses of pembrolizumab to the neoadjuvant setting saw an improvement in this two-year event free survival to 72% for the neoadjuvant therapy compared to 49% for the adjuvant therapy. That was quite an outstanding change. And again, noting the power of neoadjuvant treatment, really dictating the impact of anti PD-1, again, just with 3 doses moving from adjuvant into the neoadjuvant setting, and I think all of us were somewhat surprised to see that magnitude of a benefit. But it set up the current study very well, where we now look at combination therapy. Dr. Diwakar Davar: So let's move on to the phase 3 NADINA trial. Do you want to perhaps discuss the study design, particularly focusing on the EFS primary endpoint and maybe also touching on the different schedules? So, SWOG S1801 was a neoadjuvant study of 3 cycles of pembrolizumab and how did that compare and contrast to the neoadjuvant combination that was studied in NADINA? Dr. Jason Luke: Well, as you alluded to, NADINA investigated the regimen of nivolumab plus ipilimumab and compared that against adjuvant therapy with nivolumab alone. So, in the study, as you alluded, the dose and schedule of the two drugs used was nivolumab at 3 milligrams per kilogram, and ipilimumab with 1 milligram per kilogram. That was based on a series of signal finding and safety studies that had been previously done by the same group of authors identifying that as the optimal treatment regimen. And it's worth noting that's slightly different than the labeled indication that's generally used for those same drugs for metastatic melanoma, albeit that the NCCN also endorses this schedule. So, in the trial, 423 patients were randomized, 1:1 to receive either neoadjuvant therapy with those 2 doses of nivolumab plus ipilimumab as compared with standard adjuvant therapy with nivolumab following surgery.   Now, one interesting tweak was that there was an adaptive nature to the study, meaning that patients had a fiducial placed at the index lymph node, and after the neoadjuvant therapy in that arm, that lymph node was removed. And if the patient had a major pathological response, they did not go on to receive the adjuvant portion of the treatment. So it was adaptive because those patients who did very well to the neoadjuvant did not require the adjuvant portion. And in those patients who did not achieve a major pathological response, they could go on to have the adjuvant therapy. And that also included the BRAF therapy for those whose tumors were BRAF mutants.  It's also worth pointing out that the definition of event free survival was slightly different than in the S1801 study that was alluded to just a second ago. And here, EFS was defined from the date of randomization until progression due to melanoma or due to treatment. So that's slightly different than the definition in the S1801 trial. So, a somewhat complicated study, but I really applaud the authors because I think this study does mirror what we would likely be doing in actual clinical practice.  Dr. Diwakar Davar: So, just to briefly summarize the efficacy, and then to get your comments on this, the path response, the PCR rate was 47%. The major pathologic response rate, which is the proportion of patients with between 0% to 1/10% of residual viable tumors, was about 12%. And for a major pathologic response rate of 0% to 10% of 59%. And then the rest of the patients had either pathologic partial response, which was 10% to 50%, or pathologic non response or 50% or greater residual viable tumor, all assessed using central pathology grades. The one year RFS was 95% in the FDR patient population versus 76% in the pathologic partial response patient population, 57% in the pathologic non response patient population. So how do you view these results? Can you context the FDR rates and the EFS rates from NADINA relative to nivo-rela and also potentially SWOG 1801? Dr. Jason Luke: Well, I think these are very exciting results. I think that for those of us that have been following the field closely, they're actually not especially surprising because they mirror several studies that have come before them. When we put them in context with other studies, we see that these rates of major pathological response are consistent with what we've seen in phase 2 studies. They're relatively similar. Or I should say that the results from nivolumab and relatlimab, which was also pursued in a phase 2 study of somewhat similar design, are somewhat similar to this. So, combination immunotherapy does look to deliver a higher major pathological response than pembrolizumab alone, as was known in S1801. Which of course, the caveat being is these are cross control comparisons that we need to be careful about. So I think all of these are active regimens, and I think adding a second agent does appear to enhance the major pathologic response rates. When we look at the event free survival, we see something similar, which is that numerically it looks to be that combination immunotherapy delivers a higher event free survival rate. And that looks to be rather meaningful given the difference in the hazard ratios that were observed between these various studies. And here in the NADINA study, we see that 0.3 hazard ratio for EFS is just extremely impressive.  So the abstract then, from ourselves, out of these specific studies, what does this mean more broadly in the real world, where patients exist and the rest of the landscape for clinical trials? I think we can't take enough time to stop for a second and just think about what a revolution we've come forward in with immune checkpoint blockade and melanoma. When I started my career, now, more than 15 years ago, melanoma was the cancer that made cancer bad. And now here we say, in the highest risk of perioperative patients, we can deliver 2 doses of nivolumab and ipilimumab, and essentially half of the patients then don't need to go on, and more than half the patients don't need to go on to have a full surgery and don't need adjuvant therapy. And from what we could tell of a very, very low risk of every heavy recurrence of melanoma. Of course, there's the other half of patients where we still need to do better, but these are just fantastic results and I think highly meaningful for patients.   In the context of ongoing clinical trials, another abstract that was presented during the meeting was the update to the individualized neoantigen therapy, or V940 with pembrolizumab or against pembrolizumab alone. That's the KEYNOTE-942 study. In that study, they presented updated data at two and a half years for relapse free survival, noting a 75% rate without relapse. So those results are also highly intriguing. And these are in a similar population of very high risk patients. And so I think most of us believe that neoadjuvant therapy with this study in NADINA is now confirmed as the priority approach for patients who present with high-risk stage 3 disease. So that would be bulky disease picked up on a scan or palpable in a clinic. I think essentially all of us now believe patients should get preoperative immunotherapy. We can debate which approach to take, and it may vary by an individual patient's ability to tolerate toxicity, because, of course, multi agent immunotherapy does have increased toxicity relative to anti PD-1 alone. But we'll have to wait now for the full phase 3 results from the V940 individualized neoantigen therapy. And if those come forward, that will be an extremely attractive approach to think about for patients who did not achieve a major pathological response to neoadjuvant therapy, as well as of course to the other populations of patients with melanoma where we otherwise currently give adjuvant therapy stage 2B all the way through stage 4 resected. It's an amazing time to think about perioperative therapy in melanoma. Dr. Diwakar Davar: So this is clearly outstanding data, outstanding news. Congratulations to the investigators for really doing what is an investigative initiated trial conducted across multiple continents with a huge sample size. So this clearly appears to be, at this point in time at least, a de facto standard. But is this going to be FDA-approved, guideline-approved, or is it possible in your mind? Dr. Jason Luke: Well, that's an interesting question. This study was not designed with the intent to necessarily try to register this treatment regimen with the FDA. One would have to take a step back and say, with how powerful these data appear, it sort of seemed like it would be too bad if that doesn't happen. But all the same, I think the community and those of us who participate in guideline recommendations are fully supportive of this. So, I think we will see this move into compendium listings that support insurance approval, I think, very, very quickly. So, whether or not this actually becomes formally FDA approved or is in the guidelines, I think this should become the standard approach that is considered for patients, again presenting with high-risk stage 3 disease.  Dr. Diwakar Davar: Fantastic. So now we're going to go in and talk about a slightly different drug, but also from the melanoma context, and that is the safety and efficacy of RP1 with nivolumab in the context of patients with melanoma who are PD-1 failures. So, this is Abstract 9517. And in this abstract, our academic colleagues essentially talked about these data, and we'll start by describing what RP1 is. RP1 essentially is a HSV-1 based oncolytic immunotherapy. And RP1 expresses GM-CSF as well as a fusogenic protein, GALV-GP-R-. And in this abstract, Dr. Michael Wong from MD Anderson and colleagues are reporting the results of IGNYTE, which is a phase I trial of intratumoral RP1 co-administered with systemic nivolumab in patients with advanced metastatic treatment refractory cutaneous melanoma. And the data presented in this abstract represents data from a registration directed, abbreviated as RD, registration directed cohort of RP1 plus nivolumab in PD-1 refractory melanoma. So, let's start with the description of the cohort.  Dr. Jason Luke: Right. So, in this study, there were a total of 156 patients who were presented, and that included an initial safety and dose finding group of 16, as well as the RD cohort, as you noted, of 140 patients. And it's important to point out that this was a cohort that was selected for a very strict definition of progression on anti PD-1, or a combination immunotherapy as their immediately prior treatment. So, all of the patients in the cohort had exposure to anti PD-1, and 46% of them had anti PD-1 plus anti CTLA4, nivolumab and ipilimumab as their immediately prior therapy. This was also a group of relatively high-risk patients when one considers stage. So, within the stage 4 population, the entry here included 51% who had stage M1B, C, and D melanoma. And that is worth pointing out because this is an injectable therapy. So, trials like this in the past have tended to be biased towards earlier stage, unresectable or metastatic melanoma, meaning stage 3B, 3C, 3D and then stage 4m1a. Again, to emphasize the point here, these were pretreated patients who had a strict definition of anti PD-1 resistance, and over half of them, in fact, had high-risk visceral metastatic disease.  In that context, it's very interesting to observe that the overall response rate was described in the total population, as 31%, and that included 12% who achieved complete response. And so, again, to make sure it's clear, we're talking about a treatment where the oncolytic virus is injected into one or multiple sites of recurrent disease, and then the patients administer nivolumab as per standard. And so, I think these data are quite intriguing. Again, such a high- risk population and their maturity now, with a follow-up of over a year, I think, makes this look to be a very interesting treatment option.  Dr. Diwakar Davar: I guess on that topic of mature follow-up, it probably would be important for us to inform our audience that the top line data for the primary analysis was actually just released, I think, earlier today, and wherein the central confirmed objective response rate was 34% by modified RECIST and 33% by RECIST, clearly indicating that these responses, as you noted, very treatment refractory patient population, these responses were clearly very durable. So, you mentioned that there were responses seen in uninjected visceral lesions, responses seen in both PD-1 and PD-1 CTLA-4 refractory patients. Can you talk a little bit about the response rate in these high-risk subgroups, the uninjected visceral lesions, the patients who had both combination checkpoint and epidural refractory response rate by primary PD-1 resistance.  Dr. Jason Luke: Sure. You know, I think, again, to emphasize this point in the study, we saw that there were responses in the non-injected lesions, and I think it's really important to emphasize that. Some have referred to this as a putative abscopal like effect, similar to what is described in radiation. But it implies that local treatment with the oncolytic virus is triggering a systemic immune response. In the higher risk patient population, we'll note that whereas the overall response rate in PD-1 refractory patients was 34%, in the combination of PD-1 and CTLA-4 refractory patients, the response rate was 26%. So, [this is] still very good. And when we looked at that split by stage, as I alluded to before, in the population of patients that had, what you might call earlier unresectable diseases, so 3B through 4A, the response rate was 38%, and in the stage 4 M1b through M1d, it was 25%. So slightly lower, but still very good. And that would be as expected, because, of course, the patients with visceral metastatic disease have more advanced disease, but those response rates look quite good. Again, looking at the combination refractory population as well as the more high-risk disease. Dr. Diwakar Davar: So, clearly, these are very promising data and exciting times for multiple investigators in the field and the company, Replimune, as well. So, what are the next steps? I believe that a registration trial is planned, essentially, looking at this with the goal of trying to get this combination registered. Can you tell us a little bit about IGNYTE-3, the trial design, the control arm, and what you foresee this trial doing over the next couple of years?  Dr. Jason Luke: So, as this agent has been maturing, it's worth pointing out that the company that makes this molecule, called RP1, but I guess now we'll have to get used to this name vusolimogene oderparepvec as the actual scientific term, they have been having ongoing discussions with the FDA, and there is the potential that this agent could come forward on an accelerated path prior to the results being released from a phase 3 trial. That being said, the phase 3 confirmatory study, which is called the IGNYTE-3 study, is in the process of being launched now. And that's a study investigating this molecule in combination with nivolumab, as was alluded to earlier, and a randomized phase 3 design, where that combination is compared with a physician's choice, essentially a chemotherapy-based option.   In that study, it will be 400 patients with stage 3B through stage 4; patients will have progressed on anti PD-1, either as a combination or in sequence, and then come on the study to be randomized to either vusolimogene oderparepvec plus nivolumab versus that physician's choice. And the physician's choice includes chemotherapy agents, but also nivolumab plus relatlimab as another option, or an anti PD-1 monotherapy, if that's deemed to be a reasonable option by the treating investigator. And the primary endpoint of that study is overall survival. And unfortunately, in this highly refractory patient population, that's something that may not take long to identify with key secondary endpoints of progression free survival, as well as overall response rate. I'm quite enthusiastic about this study, given these data, which have now been centrally confirmed as you alluded to before. I think this is a very exciting area of investigation and really crossing my fingers that this may be perhaps the first locally administered therapy which does appear to have a systemic impact that can hold up in phase 3. Dr. Diwakar Davar: Very, very, very exciting results. And I guess it's worthwhile pointing out that this company also has got, I think, multiple studies planned with both RP1 and cutaneous squamous cell carcinoma in a solid organ transplant patient population where single agent activity has already been reported by Dr. Migden at prior meetings, as well as a novel trial of potentially RP2 metastatic uveal melanoma. So we'll now pivot to Abstract 6014. So, 6014 is a drug by a company known as Merus. Essentially, it's a very novel agent. Merus essentially is a company that is specialized in making bicyclics and tricyclics. And these are not bicycles or tricycles, but rather drugs that essentially are bispecific antibodies. And Merus essentially has come up with petosemtamab. I think we're going to have to figure out better names for all of these drugs at some point. But petosemtamab, or MCLA-158, essentially is a bicyclic, targeting both EGFR as well as LGR-5. So EGR-5, of course, is a known oncogenic driver in multiple tumor types, squamous, including non small cell lung cancer, cutaneous squamous cell carcinoma, but also head and neck squamous cell carcinoma. And LGR-5 essentially is leucine-rich repeat-containing G-protein coupled receptor 5, but it's a receptor in cancer stem cells and certainly highly expressed in head neck squam. And MCLA-158, or petosemtamab is a IgG one bispecific with ADCC-activity because of IgG1 backbone co-targeting EGFR and LGR5. Merus had earlier results that evaluated petosemtamab monotherapy. They defined the RP2D and second- and third-line head and neck blastoma patients with a respectable response rate of 37% investigator-assessed ORR with six months median DoR, and this was published by Ezra Cohen about a year or so ago.  In this abstract, Dr. Fayette and colleagues report on the results of the MCLA-158-CL01 trial, which is a trial of pembrolizumab plus petosemtamab in one front line head and neck squamous cell population. So maybe let's start with the description of the cohort. And it is a small trial, but we'll be able, I think, to dig into a little bit about why this might be exciting. Dr. Jason Luke: Yes. So, as alluded to, it's not the biggest trial as yet, but there were 26 patients with anti PD-1 treatment naive head and neck squamous cell carcinoma. And all the patients in the study did receive, as you alluded to, pembrolizumab plus petosemtamab. Based on the label for pembrolizumab, all the patients in this study were PDL-1 positive. So that's one point that it's worth pointing out to make sure that that's understood. This is the population of patients who would be expected to benefit from pembrolizumab in the first place. Now, in the abstract, they reported out only 10 response evaluable patients, but they updated that in the actual slides of presentation at the meeting. So among 24 patients that were alluded to, 67% were described as having had a response, although some of those were yet to be confirmed responses. And when it was evaluated by PDL-1 status, there didn't seem to be a clear enrichment of response in the PD-1 positive more than 20% group, as compared to the 1-19% group. That isn't especially surprising because that was a trend that one would see, presumably with pembrolizumab alone. But overall, I think these data are pretty exciting in terms of a preliminary study. Dr. Diwakar Davar: You know, you mentioned that the objective response rate was high, almost 60-something%. The prognosis of these patients is generally poor. The OS is typically thought of as between 6-15 months. And based on KEYNOTE-048, which was led by Dr. Burtness and colleagues, the standard of care in the setting is pembrolizumab +/- platinum based chemotherapy regimens. Allowing for the fact that we only have 10 patients here, how do you think these results stack up against KEYNOTE-048? And you made a very important point earlier, which was, by definition, pembro is on label only for the CPS. So PDL-1 score, at least in head and neck squamous cell carcinoma CPS and not TPS. But in the CPS 1% or greater patient population, where pembro is on label, how do these results stack up against the KEYNOTE-048 results. Dr. Jason Luke: Right. KEYNOTE-048 is considered the seminal study that dictates frontline treatment in head and neck cancer. And before we dive into this too far, we do want to acknowledge that here we're comparing 26 patients versus a phase 3 trial. So, we're not trying to get too far ahead of ourselves, but this is just a preliminary comparison. But in KEYNOTE-048, as you alluded to, two regimens were superior to chemotherapy. One was the pembrolizumab monotherapy, as well as pembrolizumab plus chemotherapy. So again, the study overall survival, of course, was much higher, the PDL-1 positive subgroup, which is what dictated the unlabeled use of this. But response to pembro monotherapy in that population of patients is still modest. We're talking about upwards of 20-30%. So, if you compare that to, again, preliminary evidence here from this trial of only 24 patients, that response rate of 60% seems extremely high. And so even if that were to come down somewhat in a larger data series of patients, that still looks to be quite promising as a treatment regimen, that might eventually even be chemotherapy sparing for this population of patients. I think this raises a lot of eyebrows that perhaps this dual targeting approach, EGFR and LDR-5, may bring something really important to the field that evolves it. Dr. Diwakar Davar: So, what are the next steps for petosemtamab? You mentioned that the activity was interesting. Are we going to see a larger trial? Any thoughts on where things are going to go?  Dr. Jason Luke: Well, based on the phase 2 data of petosemtamab alone, even without pembrolizumab, the molecule had already been given fast track designation by FDA, which means allowing for greater communication between the drug sponsor in the FDA and designing a seminal study design. One would assume that this trial will be rapidly expanded quite greatly, perhaps to 100 or 200 patients, to try to flush out what the real response rate is in a more meaningful number of patients. But I think these data will probably also trigger the design and probably near-term evaluation or expedited acceleration of a phase III clinical trial design that would potentially validate this against the current standard of care. So, I'm pretty excited. I think we'll see a lot more about this agent in the relatively near future. Dr. Diwakar Davar: So, finally, we'll pivot to the last abstract that we're going to talk about, which is Abstract 2504. It's a relatively interesting target, CCR8 monoclonal antibody. But this is the efficacy and safety of LM-108, and LM-108 is an anti CCR8 monoclonal antibody that is being developed by LaNova Medicine. And the results that are described, actually a pool set of results of combinations of LM-108 with anti PD-1, two separate anti PD-1, in patients with gastric cancer, mostly done ex-U.S., which is interesting because of this patient population, and it's a pool result of several, 3 phase 1 and 2 studies.  LM-108 is an Fc-optimized anti CCR8 monoclonal antibody that selectively depletes tumor infiltrating Tregs. The abstract reported a pooled analysis of three phase 1, 2 trials with 3 different NCT numbers that all evaluated the efficacy of LM-108 and anti PD-1 in patients with gastric cancer. So, let's start with the description of the cohort. Maybe, Jason, you can tell us a little bit about before you start, as you describe the cohort, sort of what we know, editorially speaking, about the difficulty with which Tregs depletion has been tried and obviously failed up until now in the tumor microenvironment. Dr. Jason Luke: Right. I think that's a really interesting comment. And so, for decades, in fact, targeting regulatory T-cell to alleviate immune exclusion in the tumor microenvironment has been of interest in immuno-oncology. And in preclinical mouse models, it seems quite clear that such an approach can deliver therapeutic efficacy. However, by contrast, in human clinical trials, various different Treg depleting strategies have been attempted, and there's really little to no evidence that depleting Tregs from human tumors actually can deliver therapeutic responses. And by that we're referring to CD-25 antibodies. The drug ipilimumab, the CTLA-4 antibody, was punitively described as a Tregs depleter preclinically, but that doesn't seem to be the case in patients. And so, in that background, this is quite an eye raiser that an anti CCR8 antibody could be driving this effect. Now, before we talk about the results of this trial, I will point out, however, that given the Fc-optimization, it's entirely possible that the Tregs are being depleted by this mechanism, but that more could also be going on. Because Fc gamma RII binding by this antibody that could be nonspecific also has the potential to trigger immune responses in the tumor microenvironment, probably mediated by myeloid cells. So I think more to come on this. If this turns out to be the first meaningful Tregs depletor that leads to therapeutic efficacy, that would be very interesting. But it's also possible this drug could have multiple mechanisms.  So, having said all of that, in the clinical trial, which was a pooled analysis, like you mentioned, of LM-108 in combination with anti PD-1 of a couple different flavors, there were 48 patients treated either with LM-108, with pembrolizumab, or with toripalimab, which is another anti PD-1 antibody. On the drug combination was, generally speaking, pretty well tolerated, noting grade 3 treatment related adverse events in the range of 38%, which is somewhat expected given combination immunotherapy. We talked about nivolumab and ipilimumab before, which, of course, gives even higher rates of immune-related adverse events, with the most common toxicities being anemia, lipase elevations, rash, ALC decrease; albeit, quite manageable. Dr. Diwakar Davar: So, what about the objective response rate? Can you contextualize the efficacy? And as you do that, maybe we'll think about what you'd expect in the context of, say, gastric cancer, especially in patients who've never really had a prior checkpoint inhibitor before. What do you think about the ORR? What do you think about the relative efficacy of this combination? Dr. Jason Luke: Well, so, in the study, they described overall response rate in the 36 patients as 36% and described immediate progression for survival of about 6.5 months. And so that was among patients who were treatment naive. And in second-line patients, they actually described an even higher response rate, although it was only 11 patients, but they're at 64%. And so, I think those data look to be somewhat interesting. When I was actually scrutinizing the actual data presented, it was of some interest to note that the quality of responses seemed to be about as good on the lower dose of LM-108, so 3 milligrams per kilogram as compared to 10 milligrams per kilogram. I think there's definitely more to learn here to try to optimize the dose and to fully understand what the overall efficacy of this treatment combination would be.  I would emphasize that in this disease, I think novel treatment strategies are certainly warranted. While anti PD-1 with chemotherapy has moved the needle in terms of standard of care treatment, it's really only a minor subset of patients who derive durable long-term benefit like we normally associate with immune checkpoint blockade. I think these are preliminary data. They're very intriguing.   You alluded to earlier that this population of patients was an Asian data set, and it is well known that the efficacy of chemotherapy and immunotherapy does appear to be somewhat enhanced in Asian populations, and that goes to distributions of metastasis and tumor microenvironment effects, etc. Very difficult to try to tease any of that out in this abstract, other than to look at these data and suggest that this is pretty interesting, both from a novel therapeutic approach, we talked about the Tregs consideration, but also straight up on the efficacy because I think if these data could hold up in a larger number of patients, and particularly in a western population of patients, I think it would be very intriguing. Dr. Diwakar Davar: Certainly, ASCO 2024 had a lot of interesting data, including data from targeted agents, the LAURA trial, ADCs. But just focusing on the immune therapy subset, we certainly saw a lot of great advances in patients who were treated with neoadjuvant as well as relapse refractory disease in the context of RP1 and then a couple of newer agents such as this petosemtamab as well as LM-108. And of course, we cannot forget to highlight the extended DMFS data from the pembro vaccine study from KEYNOTE-942.  Jason, as always, thank you for taking a little bit of time out of your extremely busy schedule to come and give us insights as to how these agents are impacting the landscape. We really value your input and so thank you very much.  Dr. Jason Luke: Thank you for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for your time today. You will find the links to all the abstracts that we discussed in the transcript of this episode. And finally, if you value the insights that you hear on this podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. So, thank you.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:   Dr. Diwakar Davar   @diwakardavar   Dr. Jason Luke   @jasonlukemd      Follow ASCO on social media:    @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn      Disclosures:       Dr. Diwakar Davar:     Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences    Consulting or Advisory Role: Instil Bio, Vedanta Biosciences    Consulting or Advisory Role (Immediate family member): Shionogi    Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences    Research Funding (Inst.): Zucero Therapeutics    Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy       Dr. Jason Luke:    Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX    Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine    Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure    Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)    Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Welcome back to another episode of Crawfordsville Connection! This week we are joined by Jeremy Lemus, the Executive Director of the Montgomery County Leadership Academy (MCLA). Jeremy shares all about MCLA and their programs - High School Leadership Program, Signature Program, and soon-to-be new program Liderazgo 54. Yodel Community Calendar: https://events.yodel.today/crawfordsville  To ask any questions about this podcast or to submit topic ideas, please email Sarah Sommer at ssommer@crawfordsville-in.gov 

On todays episode of the Crease Dive we talk about everything happening in the lacrosse world from the ACC getting beat down, to PLL Free Agency, to previewing this weekends games and then finally interviewing Rory "Pops" Sanders who plays with his son Wes and is coached by his son Ethan.

Ty is an award-winning children's book author, literacy advocate, captivating motivational speaker, and honorary Doctorate recipient. In 2011 he founded Big Head Books, LLC, a literacy organization that aims to introduce children to the joys of reading. A three-time TedX presenter, Ty believes that literacy is the foundation for a successful life and promotes it with humor and enthusiasm. Ty's work as an author and literacy advocate earned him an honorary Doctor of Humane Letters degree from MCLA, the Massachusetts inaugural Martin Luther King Jr. Content of Character Award, and citations from the Massachusetts Governor, Senator, and the House of Representatives. Ty's books have been featured on CNN, NBC Nightly News, The Steve Harvey Show, PBS and countless other media outlets. In 2012, Ty's books were gifted to former First Lady Michelle Obama by his hometown mayor. He is the co-founder of the Read or Else movement and Danny Dollar Academy. In this episode you'll learn:  Catch up on Ty's social media account: Website: https://tyallanjackson.com/about-ty/  Facebook:https://www.facebook.com/tyallanjackson/  Instagram:https://www.instagram.com/ty_allan_jackson/?hl=en  Twitter:https://twitter.com/TyAllanJackson =TikTok: https://www.tiktok.com/@tyallanjackson GoBundance LHI Assesment: ⁠⁠www.gobundance.com/lhi⁠⁠ Want to listen to Tribe of Millionaires? Spotify: https://podcasts.apple.com/us/podcast/tribe-of-millionaires-podcast/id1110145229 Apple: https://open.spotify.com/show/47lZ1BcVeRs1C4D8b7kbGI Learn More About Our Tribe! https://www.gobundance.com/ Watch How To Profit From Your Brand | Mark Lack Ep 241 https://www.youtube.com/watch?v=OLYFjltV69s Want to connect with our community? Instagram: https://www.instagram.com/gobundance Facebook: https://www.facebook.com/gobundance Twitter: https://twitter.com/GoBundance Tribe of Millionaires Podcast by GoBundance is the podcast for healthy wealthy generous people who choose to live epic lives. Each week, we connect with featured guests and GoBundance members to bring you the best in our community. #gobundance #tribeofmillionaires #grablifebig

Episode 17: Lisa Chamberlain - The Chamberlain Group By Zurie Adams In 1999, Lisa Chamberlain co-founded the Chamberlain Group, which serves an international clientele of medical device manufacturers, teaching institutions, and hospitals, providing anatomy for the development and training of surgical and interventional procedures. Prior to that, Lisa graduated from Princeton and attended the Yale School of Drama in the MFA program in Theatre Management. She also worked for 13 years in New York in film and television production before moving to the Berkshires in 1995 to produce visual effects for feature films such as THE MATRIX. On this episode of Thinking Like A Region, Lisa sits down with MCLA alumna Zurie Adams to discuss how her background in the arts enabled her to start her own business creating anatomical models for medical training, through skillsets such as creativity, ingenuity and building projects from the ground up. You can find the transcript for this episode here: https://tinyurl.com/LC-TLAR Thinking Like A Region is a production of the C4 Initiative: Berkshire County's Creative Compact for Collaborative and Collective Impact, based in Berkshire County, Massachusetts, and grant-funded by the National Endowment for the Arts. This podcast is produced by Leslie Appleget and Lisa Donovan. For more information about the show or the C4 Initiative, visit ⁠brainworks.mcla.edu/c4

Episode 16: Lisa Dent - MASS MoCA by Erick Ramos-Jacobo  Episode host Erick Ramos-Jacobo is a senior at MCLA. In this episode of Thinking Like a Region, Erick interviews Lisa Dent, Director of Public Programs at MASS MoCA. The two discuss Dent's multidisciplinary career and the influence her career as a curator, designer, art critic, and more has had in supporting her new leadership position.  “I am a black woman who loves to sing in order to feel heard, and I'm so happy when I'm able to be in community with others.” “I think the skills that I bring to MASS MoCA are the fact that I have had a multidisciplinary life.” This episode focuses on the creative capacities of project management/development, self-advocacy, and public speaking learned from theatre-making and close-looking, interpretation and critical thinking taught by museums.  You can find the transcript for this episode here: https://bit.ly/TLAR-LDMM Thinking Like A Region is a production of the C4 Initiative, Berkshire County's Creative Compact for Collaborative and Collective Impact, based at Berkshire Regional Planning Commission in Pittsfield, MA, and grant-funded by the National Endowment for the Arts. This podcast is produced by Leslie Appleget and Lisa Donovan. For more information about the show or the C4 Initiative, visit brainworks.mcla.edu/c4. THIS EPISODE'S VOICES: Lisa has been in the field for close to 30 years, bringing enthusiasm, humor and heart to her work everyday. This has included her creative practice as well as collaborations and management of larger, artistic projects. She has owned and managed departments of small, mid-size, and large organizations through the lens of inclusion, equity, and anti-oppression. Her background includes work in the visual arts, publishing, theater, and film, making her one of the few professionals deeply engaged with artists and colleagues across multiple genres. Lisa received her BFA from Howard University, her MFA from New York University's Tisch School of the Arts, and completed the Whitney Museum Independent Study Program in curatorial studies. She has served on several juries and committees and is currently a board member of Triple Canopy. Erick Ramos-Jacobo is an immigrant educator, curator, and social practitioner born in Zacatecas, Mexico. Renowned Brazilian Pop artist and Parque Lage professor, Bruno Miguel, noted him as “One of the most promising young curators” (Defining Moments, MASS MoCA, 2022). He's recognized for his work in the arts, particularly in collaboration with organizations like MASS MoCA, Barrington Stage Company, Assets 4 Artists at MASS MoCA, and Madison MoCA. Erick has had the privilege of working alongside curator and educator Dr. Laura Thompson on exhibitions and educational programs featuring notable artists such as Bruno Miguel, Shaun Leonardo, Anne Samat, and Federico Uribe. His passion lies in leveraging the power of the arts to build healthier, more vibrant, and equitable communities for immigrant individuals, with a special focus on museums as a starting point. Erick's curatorial work and educational development are currently on view at MASS MoCA and his newest collaboration, Metamorphosis|Metamorfosis, will open September 2023 at Madison MoCA.

Episode 15: Andy Wrba - Mill Town Foundation By Zurie Adams Andy Wrba is a Berkshire musician and educator who, in 2012, founded the Berkshire Jazz Collective, which supports the county by creating music that features local artists. For nine years (2014-2023) he served as the Music Director at the Darrow School in Lebanon, NY. Currently, he is the program manager of Mill Town Foundation where he oversees community programs and partnerships while continuing to curate and produce events such as the Bosque Summer Concert series, Lennox Jazz Stroll, and Tanglewood in the City. In addition to his educational and community programming work, from 2005-2012 he performed all over the U.S. in a band, Barefoot Truth, producing several full-length albums and EPs, becoming a symbol of independent music success, acquiring over 50 million streams on Spotify and Pandora. In this episode of Thinking Like A Region, MCLA student Zurie Adams has a discussion with Andy Wrba about how his life as a musician equipped him with skills such as dedication, multi-tasking and patience, which he has transferred to other areas of his life. You can find the transcript for this episode here: https://tinyurl.com/AW-TLAR Thinking Like A Region is a production of the C4 Initiative: Berkshire County's Creative Compact for Collaborative and Collective Impact, based in Berkshire County, Massachusetts, and grant-funded by the National Endowment for the Arts. This podcast is produced by Leslie Appleget and Lisa Donovan. For more information about the show or the C4 Initiative, visit brainworks.mcla.edu/c4

Welcome to the first episode of a new podcast series from Lacrosse Bucket: Chained Cages. This series explores the history of former varsity lacrosse programs who have gone defunct. Some live on at the club level and some may not. This first episode explores the history Arizona lacrosse during its varsity years from 1964-1966. The Wildcats were the first varsity program west of the Mississippi River and in their short time found some good success. The program continues today at the club level, playing in the MCLA. You can find out more about Arizona lacrosse by visiting the program's website, where they have a good amount of further information about the history of the program. This podcast just scratches the surface of the stories and characters that made up the Wildcats program during its infancy and through its varsity years. -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Subscribe You can subscribe to the Lacrosse Bucket Youtube Channel here: https://www.youtube.com/channel/UCVdz... Listen You can listen to the Lacrosse Bucket Podcast on.. Apple Podcast: https://itunes.apple.com/us/podcast/l... Spotify: https://open.spotify.com/show/2S7Sv5o... Google Podcast: https://www.google.com/podcasts?feed=... Read Go to Lacrossebucket.com for all the latest lacrosse news and notes! Connect You can connect with Lacrosse Bucket on.. Twitter: @LacrosseBucket Facebook: @LacrosseBucket Instagram: @lacrosse_bucket_ --- Support this podcast: https://podcasters.spotify.com/pod/show/lacrosse-bucket/support

On today's episode, we speak with Tom West of Bolles School in Jacksonville and Ken Lovic head coach at Georgia Tech and president of the MCLA. Coach West recapped their 2023 season which ended in the state final, the rise of the Bolles program, and the launch of Southern Fuse recruiting camp. Then, Coach Lovic covered the the evolution of the Georgia Tech program into an MCLA blue blood and what's next for the MCLA this summer. The Lacrosse Playground Podcast Network is presented by Epoch Lacrosse.  Website: https://lacrosseplayground.com/ Twitter: https://twitter.com/LaxPlayground Instagram: https://www.instagram.com/lacrosseplayground/ Facebook: https://www.facebook.com/LacrossePlayground/

For episode 57, we first head back to Alabama to speak with Hoover head coach John Wiitig. He is a 2016 Hoover grad and has worked his way up from volunteer to junior varsity head coach to varsity assistant coach and now he's been the head coach since 2022. We discussed why he got into coaching, how he delegates game day decision making, and his philosophy on scheduling out of state competition. Flagler assistant coach James Foote joins us for our second interview. We covered his path from coaching NCAA D2 and high school at the same time, to being an MCLA head coach, and ultimately coming back to Florida to coach at Flagler. Coach has been sharing a lot of game clips on twitter recently so we also chatted about his plan of attack for film study. The Lacrosse Playground Podcast Network is presented by Epoch Lacrosse.  Website: https://lacrosseplayground.com/ Twitter: https://twitter.com/LaxPlayground Instagram: https://www.instagram.com/lacrosseplayground/ Facebook: https://www.facebook.com/LacrossePlayground/ Discount code: PLAYGROUND15 to save 15% on your first order from Rhoback

Spire is a sports academy in Northeast Ohio, and it's the latest among a wave of prep schools that deliver a unique offering to aspiring lacrosse players. With world-class facilities and a variety of academic programs, they're diving into the lacrosse scene feet first. The eighth sport on campus, Spire brought in JD Harkey as head coach. A UMBC lacrosse alum turned lawyer turned MCLA national champion coach turned MIAA coach, he joined Spire last summer and this week, announced that he'd added Duke All-American and PLL Redwoods midfielder Nakeie Montgomery to his staff.  Harkey, Montgomery and Spire ambassador Kyle Harrison join IL's Terry Foy to discuss how they got to this point and what comes next.

Michael Ward @OneManRide reviews the MSLA preseason rankings and analyzes Western Reserve and Culver's schedule. We finish with a little MCLA talk after he saw #2 Georgia Tech dispatch Alabama. The Lacrosse Playground Podcast Network is presented by Epoch Lacrosse.  Website: https://lacrosseplayground.com/ Twitter: https://twitter.com/LaxPlayground Instagram: https://www.instagram.com/lacrosseplayground/ Facebook: https://www.facebook.com/LacrossePlayground/ Discount code: PLAYGROUND15 to save 15% on your first order from Rhoback

Michael Ward @OneManRide gives his midwest state champion picks, discusses his experience in Bloomington, Indiana at the Indiana, Purdue, Kentucky, Louisville scrimmage, and his upcoming trip to Oxford, Mississippi to watch Alabama's MCLA team. Lacrosse Playground's podcast for takes, stories, and interviews. The Lacrosse Playground Podcast Network is presented by Epoch Lacrosse.  Website: https://lacrosseplayground.com/ Twitter: https://twitter.com/LaxPlayground Instagram: https://www.instagram.com/lacrosseplayground/ Facebook: https://www.facebook.com/LacrossePlayground/ Discount code: PLAYGROUND15 to save 15% on your first order from Rhoback

Platform's recruitment manager Will Clarkson sits down with his former lacrosse college teammate Cody Clark to discuss his experience in the MCLA, his advice on how to study overseas and much more!

Tucker La Belle is an Ohio native in his first year as head coach at NAIA Clarke in Iowa. We covered his very unique path to becoming most likely the youngest college head coach in the country, how he approached his first year of recruiting, and building the Clarke program. You may be familiar with Coach La Belle from running the Lax NAIA twitter account. In our second interview, I spoke with Brandon Schwind, a former NCAC rival, about his playing days at Upper Arlington and Wittenberg, coaching MCLA ball at Michigan State, and, the current landscape of Ohio high school lacrosse, where he is the head coach at Hudson, and his decision to join the newly formerly Spiders Lacrosse Club. The Lacrosse Playground Podcast Network is presented by Epoch Lacrosse.  Website: https://lacrosseplayground.com/ Twitter: https://twitter.com/LaxPlayground Instagram: https://www.instagram.com/lacrosseplayground/ Facebook: https://www.facebook.com/LacrossePlayground/ Discount code: PLAYGROUND15 to save 15% on your first order from Rhoback

Episode 14: Beryl Jolly - The Trustees of Reservations by Johan Serrano MCLA student Johan Serrano returns to host the final episode of the season! In this episode of Thinking Like a Region, Serrano interviews Beryl Jolly, arts manager, community engagement professional, former executive director, fundraiser, and currently working as the Vice President of Cultural Properties at The Trustees of Reservations: a land conservation and historic preservation organization dedicated to preserving natural and historical places in the Commonwealth of Massachusetts. Jolly describes her pathway to this position and the skills her early creative experiences gave her that she puts to use every day. This episode focuses on the creative capacities of communicating, adapting to different settings, attention to detail, and exploring what constitutes high-quality artworks. You can find the transcript for this episode here:https://tinyurl.com/TLAR-BRJ Thinking Like A Region is a production of the C4 Initiative, Berkshire County's Creative Compact for Collaborative and Collective Impact, based at Massachusetts College of Liberal Arts in North Adams, MA, and grant-funded by the National Endowment for the Arts. This podcast is produced by Lisa Donovan and Leslie Appleget. For more information about the show or the C4 Initiative, visit brainworks.mcla.edu/c4. THIS EPISODE'S VOICES: Beryl Jolly is the Vice President of Cultural Properties at The Trustees. Beryl joined The Trustees in June of 2020. Prior to joining The Trustees, Beryl was the Executive Director at Mahaiwe Performing Arts Center where she worked for 15 years. Johan Serrano is an arts management student at MCLA.

Episode 10: Talya Kingston - WAM Theatre by Wendy Lyons Episode host Wendy Lyons is a student at the Massachusetts College of Liberal Arts. In this episode of Thinking Like a Region, Lyons interviews Talya Kingston, dramaturg, playwright, and educator currently working as the Associate Artistic Director at WAM Theatre. WAM, an abbreviation of Where Arts and Activism Meet, is a professional theatre company in Western Massachusetts. Kingston describes her personal journey to and at WAM, WAM's mission, and how she believes that arts and activism intersect. This episode focuses on the creative capacities of public speaking, building confidence, and the effect of art on interpersonal dynamics. You can find the transcript for this episode here: https://tinyurl.com/TK-TLAR Thinking Like A Region is a production of the C4 Initiative, Berkshire County's Creative Compact for Collaborative and Collective Impact, based at Massachusetts College of Liberal Arts in North Adams, MA, and grant-funded by the National Endowment for the Arts. This podcast is produced by Lisa Donovan and Leslie Appleget. For more information about the show or the C4 Initiative, visit brainworks.mcla.edu/c4. THIS EPISODE'S VOICES: Talya Kingston is a dramaturg, playwright, and educator currently working as the Associate Artistic Director at WAM Theatre. She previously worked as a Visiting Professor of Theatre at Hampshire College. Kingston is a member of Literary Managers and Dramaturgs of the Americas, the Dramatists Guild and the Northampton Playwrights Lab, and holds an MFA from the University of Massachusetts, Amherst. Wendy Lyons is a student at MCLA studying public history.

Episode 9: Quray Clarke - MCLA Student by Jolyne Allegro Episode host Jolyne Allegro is a senior at the Massachusetts College of Liberal Arts. In this episode of Thinking Like a Region, Allegro interviews Quray Clarke, a visual artist and photographer from Queens, New York with a specialty in creative portraiture. Clarke is also a student at MCLA, providing listeners with an inside look into how MCLA's art programs translate into real-world careers in the arts. This episode focuses on the creative capacities of changing the ways we act, self-expression, community building, human connection, and building confidence. For a look into Clarke's work, visit his portfolio at https://okayarchive.com/ You can find the transcript for this episode here: https://tinyurl.com/QC-TLAR Thinking Like A Region is a production of the C4 Initiative, Berkshire County's Creative Compact for Collaborative and Collective Impact, based at Massachusetts College of Liberal Arts in North Adams, MA, and grant-funded by the National Endowment for the Arts. This podcast is produced by Lisa Donovan and Leslie Appleget. Additional technical support by Audrey Perdue. For more information about the show or the C4 Initiative, visit brainworks.mcla.edu/c4. THIS EPISODE'S VOICES: Quray Clarke is a visual artist and activist from Queens, New York with a concentration in creative portrait photography. Clarke is also a student at Massachusetts College of Liberal Arts. Jolyne Allegro is a transgender senior at Massachusetts College of Liberal Arts, studying theater and anthropology. Jo has been an active member of the arts community throughout high school and college. Her experiences in the art community have given her a unique perspective on the way that art affects people, both the creation of art, as well as the ways that taking in works of art can affect the soul.

Episode 9: Erica Barreto - MCLA Institute for Arts and Humanities by Alana O'Connor Today's episode is hosted by Alana O'Connor, a senior at the Massachusetts College of Liberal Arts. In this episode of Thinking Like a Region, O'Connor interviews Erica Barreto, a 2018 graduate of MCLA now working as the MCLA Institute for the Arts and Humanities (MCLA-IAH) Coordinator. O'Connor and Barreto discuss the role of arts in the Berkshires, along with talks about her previous work as well as her working at MCLA, and what being a collaborator of IAH entails. This episode focuses on the creative capacities of communication, translation of experiences, project management, and the ability to approach difficult conversations. You can find the transcript for this episode here: https://tinyurl.com/EB-TLAR Thinking Like A Region is a production of the C4 Initiative, Berkshire County's Creative Compact for Collaborative and Collective Impact, based at Massachusetts College of Liberal Arts in North Adams, MA, and grant-funded by the National Endowment for the Arts. This podcast is produced by Lisa Donovan and Leslie Appleget. For more information about the show or the C4 Initiative, visit brainworks.mcla.edu/c4. THIS EPISODE'S VOICES: Erica Barreto is the former Coordinator of the MCLA Institute of Arts and Humanities. Barreto graduated from MCLA in 2018 with a degree in English/Communications with a Creative Writing concentration and Arts Management. She sits on the boards of WAM Theatre and BRIDGE, and is currently the Executive Assistant to the President of the Berkshire Black Economic Council. Alana O'Connor is a senior at the Massachusetts College of Liberal Arts.

On today's Lax Goalie Rat Podcast episode, I sit down to chat with the current starting goalie at Cal,  my alma mater, Zach Blake.

Episode 5: Ben Lamb - 1Berkshire by Lisa Donovan Today's episode is hosted by Lisa Donovan, Ph.D., a professor in the Fine & Performing Arts Department at the Massachusetts College of Liberal Arts. In this episode of Thinking Like a Region, Donovan interviews Ben Lamb, Director of Economic Development at 1Berkshire. Donovan and Lamb discuss the role of the arts in economic development, Lamb's history as a student at MCLA, and projects he has been a part of across Berkshire County. Lamb shares his insights on the importance of exposing our youth to the arts, the skills employers are looking for, and how the arts can develop these skills and capacities including community engagement and working collaboratively. Listen in to hear how Lamb works to serve the arts programs across the region. You can find the transcript for this episode here: https://tinyurl.com/benTLAR Thinking Like A Region is a production of the C4 Initiative, Berkshire County's Creative Compact for Collaborative and Collective Impact, based at Massachusetts College of Liberal Arts in North Adams, MA, and grant-funded by the National Endowment for the Arts. This podcast is produced by Lisa Donovan and Leslie Appleget. Additional technical support by Audrey Perdue. For more information about the show or the C4 Initiative, visit brainworks.mcla.edu/c4. THIS EPISODE'S VOICES: Ben Lamb is the Director of Economic Development at 1Berkshire. Lamb's work focuses on what he calls ‘wraparound economic development,' which creates connective tissue between traditional and non-traditional participants in the region's economic ecosystem — most notably through his development and launch of the Berkshire Blueprint 2.0, an economic-development imperative for the region's next decade. Lisa Donovan, Ph.D. is a Professor in the Fine and Performing Arts Department at the Massachusetts College of Liberal Arts. Previously, she served as Lesley University's Director of the Creative Arts in the Learning Division. Dr. Donovan has published widely and presented across the country and internationally on arts integration, rural arts education, and arts integration assessment. She is co-director of BRAINworks and the Director of the Institute for the Arts and Humanities. She is the 2021 Recipient of the Massachusetts Arts|Learning Irene Buck Service to Arts Education Award.

Lawrenceville School assistant coach and Faceoff Academy Pennsylvania director Colby Cohen joins the show today to discuss how they prepare for game day, making in game adjustments, what young faceoff men should be focused on and briefly touch on his time as an MCLA coach at Arizona. The Lacrosse Playground Podcast Network is presented by Epoch Lacrosse and Top 66. Website: https://lacrosseplayground.com/ Twitter: https://twitter.com/LaxPlayground Instagram: https://www.instagram.com/lacrosseplayground/ Facebook: https://www.facebook.com/LacrossePlayground/ Discount code: PLAYGROUND15 to save 15% on your first order from Rhoback

We debut heartbreaking track, "The Hate," by Misty Blues, released this month as a single. We speak with Nora Zahn from the North Adams Public Library about their Summer Reading Program, and we also hear from Shirley Edgerton about the Berkshire Teaching Fellows Program — a, effort coordinating MCLA, the NAACP— Berkshire Chapter, and school districts in the County. The post Top Left Corner #159 — Junteeth & Fathers Day edition appeared first on The Greylock Glass.

Griz lacrosse head coach and Griz hockey general manager Tucker Sargent drops into the studio to talk about the history of Griz lax and UM's recent run to the Final Four of the MCLA national tournament, plus some talk about Griz hockey, the NHL, the NBA and more.

This episode of the Utah Lax Report podcast features an interview with Kyler Banks. Banks is the current head coach at the University of Utah MCLA D-II Club team, which just won the 2022 MCLA D-II National Championship. We talk about growing up in Oregon, how the club team became an MCLA team, the 2022 season and of course, the last 4 games of the MCLA National Tournament. You can listen to the latest podcast above or on Apple Podcasts or Spotify. Don't forget to subscribe and leave a rating!The Utah Lax Report podcast is sponsored by GroupSpot. Whether you're an organized high school team, a casual group of friends playing pickup, or a fully supported booster club, GroupSpot brings the team together like never before. Elevate your game and get to the finish ahead of the competition with GroupSpot.— Tim Haslam This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.utahlaxreport.com

Mike Daly (Brown) discusses the Ivy League and his transition from Tufts. Ken Lovic (GA Tech) fights tech issues to fill us in on the upcoming MCLA championships. Janinie Tucker (Johns Hopkins) talks about changes in women's lacrosse and being a published author. Anish Shroff (ESPN) talks NCAA Mens Tourney outlook and his new gig with the Carolina Panthers.

This episode of the Utah Lax Report podcast featured an interview with Taylor Redd. Redd is the current Timpview Head Coach. We chat about growing up in Virginia and Michigan, playing college lacrosse at BYU and then his coaching career which has led him to schools in Texas, BYU and now Timpview. Redd is also a data analyst at Adobe and has developed his own rankings system for the MCLA. You can find that here: https://tredd.shinyapps.io/ReddRankings/ You can listen to the latest podcast above or on Apple Podcasts or Spotify. Don't forget to subscribe and leave a rating!The Utah Lax Report podcast is sponsored by GroupSpot. Whether you're an organized high school team, a casual group of friends playing pickup, or a fully supported booster club, GroupSpot brings the team together like never before. Elevate your game and get to the finish ahead of the competition with GroupSpot.— Tim Haslam This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.utahlaxreport.com

Jamie McNealey joins to talk about what's happening in the NCLL. Kyle McQuillan from Liberty Lacrosse discusses the MCLA. Brandon Childs talks to us about the culture of York College lacrosse.

On this week's episode the fellas are once again joined by our good pal Larken Kemp to talk about the warpath all the Ivy League teams are currently on. Then we switch gears and talk about what a disaster of a weekend it was in the ACC, a scary situation in the MCLA, if any coaches should be on the hot seat, and finally wrap things up with our locks for this weekend's slate of games.

The crew goes DTA with the Minnesota Murder from UTAH State, Coach Bingham.  We get an in depth interview learning about the program, Scott's intro to lacrosse, his back story, what he puts on eggs and much much more!  

In this episode of this Utah Lacrosse Podcast, Junior Defenseman and Captain, Rylan Lemons, talks about growing up in Colorado, playing MCLA & NCAA lacrosse, traveling the country, and post-college plans.   The post Junior Defenseman & Captain Rylan Lemons appeared first on Utah Utes Lacrosse.

Karina Mattera, a current Production Assistant for ESPN and a former Guard for MCLA (Massachusetts College of Liberal Arts)Karina has an amazing basketball player and brought her passion for the game into sports media. She did everything she could to get into the sports field and has always had a passion for making videos and editing.At ESPN now she has been fortune enough to work on some amazing projects, such as some highlight packages for this years Super Bowl, working on the set of NFL Live, and much more as she explains.Karina Mattera- https://www.instagram.com/idekarina/Background Music- https://youtu.be/QfyAFxzknuw

Interview with Florida Gator goalie, team captain, and club president Matt Corazon. 

Welcome to another episode of Crawfordsville Connection. This week we are joined by Rachel Zachary Board President of the Montgomery County Leadership Academy. Rachel is here to talk to us about all of the Volunteer Opportunities available & the MCLA's new Point App. Before we talk to Rachel the Mayor gives us his top 3 things. For more information visit crawfordsville.net To submit and questions of ideas feel free to reach out to the mayor or email info@thinkbluemarketing.com

We start by diving into our venture into MCLA and it's Twitter universe full of weird brags, cool traditions, and friendly social media admins. We also give our harshest Clout Police sentence yet and then talk Twitter Beefs of the week. As always, we give the undisputed best takes in college lacrosse, including, but not limited to, the ACC being way better than the Big Ten and the upcoming Ivy / D3 matchups. (41:16) UNC midfielder Will Perry joins us and is very good at dodging all of our trap questions. He gets into the current state of the UNC team, answers some questions sent in by listeners, and discusses his potential PLL future. He is still looking for an office job though, so hit him up if you think he sounded smart. #DraftPerry Catch Will's next game on ACC Network as UNC goes up against Notre Dame on Sunday. New gear coming to our sideline swap locker soon!

Good morning lacrosse fans. Thank you for taking time out of your day for the Utah Lax Report. Don't forget to forward to a friend, it's the best way for the newsletter to grow. Let's get to it. Interview w/ Waterford Athletic Director Craig Morrisc/o Ben HaslamCraig Morris is one of a handful of people in the lacrosse community who has seen the sport grown from a few teams in the mid 90's to what it is today. He has coached at the high school and college level and was a huge part of the sanctioning effort. Please take a moment to listen to our conversation, there are tons of great nuggets of information in it. You can listen to the latest podcast above or on Apple Podcasts or Spotify. Feeling hungry? We have a lot to get through to stop reading and head to Vessel Kitchen and order my go-to, the Chicken + Grains: shredded chicken, coconut rice, quinoa, spicy house green sauce, fresno aioli, fire roasted peppers. Once you're full, continue reading! 2021 Girls High School Preseason Region RankingsThis wraps up the region rankings. Once again, I didn't come up with these, they are voted on by the coaches in the region. You can see all of the rankings in the story highlights on Instagram. Region 1File photo from the archivesThe Darts received six first place votes and will look to take the Region 1 title with head coach Makenzie Hekking at the helm, leading her alma mater.2021 Region 1 Preseason RankingsDavis (6)Weber (1)Fremont (1)RoyNorthridgeLaytonSyracuseClearfieldRegion 1 Players to WatchSam Wilkes (Davis), Macie Wood (Davis), Ava Bair (Davis), Carlie Murray (Weber), Reanna Maughan (Weber), Emma Greer (Weber), Rylee Webster (Layton), Sieara Christensen (Layton), Allie Gordon (Layton), Brooklyn Suttlemyre (Syracuse), Maggie Manley (Syracuse), Anna Bott (Syracuse).Region 3Herriman: 2019 Girls D-I ChampionsAs the defending champions, Herriman certainly has a target on its back but that was almost 21 months ago. Several key players graduated in 2020 but the foundation should be strong for the Mustangs. Bingham and West Jordan will certainly challenge for the region title. 2021 Region 3 Preseason RankingsHerriman (3)Bingham (3)West Jordan (1)RivertonCopper HillsJordanWestRegion 3 Players to WatchOlivia Rindlisbacher (Herriman), Bailee Butterfield (Herriman), Bailee Fabert (Herriman), Olivia Gilbert (Bingham), Mia Scharman (Bingham), Saige Drecksel (Bingham), Kenzi Winget (West Jordan), Emilee Algier (West Jordan), Sydnee Brinton (West Jordan), Allie Reiser (Copper Hills).Region 5It's not everyday that a new team gets the top spot. Farmington will have a lot to prove in its first season. 2021 Region 5 Preseason RankingsFarmington (4)Box Elder (1)Woods Cross (1)BountifulBonnevilleViewmontRegion 5 Players to WatchPaige Burwell (Farmington), Emily Leavitt (Farmington), Hailey Savage (Farmington), Taylor Byrd (Bonneville), Amanda Davies (Bonneville), Lyssa Hendrickson (Bonneville), Hannah Bird (Viewmont), Bekah Bargeron (Viewmont), Toree Wheatley (Viewmont).Region 6The 2020 Bengals squadThe Bengals return a ton of talent and certainly a favorite to be in at least the semifinals this season. 2021 Region 6 Preseason RankingsBrighton (4)Olympus (1)SkylineHighlandEastRegion 6 Players to WatchHaley Taylor (Brighton), Addi England (Brighton), Grace Rappl (Brighton), Kate Richards (Olympus), Maddy Larkins (Olympus), Hazel Baker (Olympus), Presley Parkinson (Highland), Sofia Patnode (Highland), Amelia Santelli (Highland), Grace Szwedko (East), Britlyn Smith (East), Lindsey Knaphus (East).Region 7File photo from the archivesAlta will look to return to glory as one of the top teams in the state. 2021 Region 7 Preseason RankingsAlta (4)Mountain Ridge (1)Lehi (1)Timpanogos (1)TimpviewMountain ViewOremRegion 7 Players to WatchCalli McDermott (Alta), Marley Webster (Alta), Kate Johnson (Alta), Kiley Mortensen (Mountain Ridge), Tessa Mortensen (Mountain Ridge), Morgan Mackey (Mountain Ridge), Nev Wilson (Mountain View), Holly Huntington (Mountain View), Kaelynn Wilson (Mountain View).Region 112020 Mountain Crest Mustangs2021 Region 11 Preseason Rankings1. Mountain Crest (5)2. Sky View (1)3. Ridgeline T4. Bear RiverT4. Green Canyon6. LoganRegion 11 Players to WatchMarley Kierstead (Bear River), Bailey Bjorn (Bear River), Savanna Pehrson (Bear River), Taryn Durham (Mountain Crest), Alicia Solano (Mountain Crest), Kamrie Wilkinson (Mountain Crest), Belle Quiggle (Ridgeline), Maddie Topham (Ridgeline), Kylee Andersen (Ridgeline).College UpdatesThe Utah Utes fell to Air Force in OT, 10-9. Branden Wilson (2G, 2A), Tyler Bradbury (1G, 3A) and Jack Barron (2G, 1A) led the Utes. Box Score | Recap | Video. When Utah announced going NCAA D-I, it was exciting to think about a Utah/Denver rivalry but let's be honest; the Utah/Air Force rivalry fits the rivalry mold much better for the time being. The Utes face Loyola next Saturday. BYU went to Colorado and faced Adams State on Friday and CSU-Pueblo on Saturday. The Cougars beat the Grizzlies, 15-1, while taking down the Thunderwolves 18-5. Here's the 2021 schedule for BYU:UVU took to the road and beat Concordia, 10-7. The Wolverines will head to Colorado for games against Adams State and CSU-Pueblo this weekend. The MCLA released its plan for something resembling a postseason this year. I think it's easy for most of us in Utah to think things are somewhat back to normal but when dealing with a nationwide organization, it's not so simple. Enter the 2021 MCLA Invitational. This sums it up: I had a thought the other day; does a shortened season last year with no season or no meaningful season this year help or hinder a players desire to play? Let's say you were a Freshman in college in 2019 at an MCLA school. You rode the bench or maybe got a little playing time. Last year, as a Sophomore, your team played 3 games and you saw no time before your season was cancelled. This year, you are a Junior in school but still a Sophomore in eligibility. Your team isn't playing or doesn't want to go to the MCLA Invitational. Does this make you want to play your Senior season more or less? Will teams be younger overall next year? What do you think? Utahns AbroadRyan Baker (Juan Diego) had 3 groundballs on defense for Bryant in a 14-8 loss to Stony Brook.Logann Eldredge (Herriman) had 4 goals and 3 assists against Kent State on Friday. Bubba Fairman (Brighton) had 1 goal and a groundball for Maryland in a 20-9 win over Michigan. Zack Franckowiak (Corner Canyon) had a groundball for Rutgers in a 11-9 upset over Penn State. Several Utahns featured in the Southern Virginia 21-16 loss to Hampden-Sydney. Box Score | Video - Tennison Schmidt (Brighton) had 6 goals and 1 assist. Chandler Wescott (Bountiful/BYU) had 4 goals and 3 assists. Dalon Hampshire (Bountiful/BYU) had 18 saves. On the Women's side at SVU, Alissa Johnson (Olympus) had 6 goals and 1 assist in a 14-13 win over Centre. Box Score | VideoNews & NotesLacrosse PhotographyMy brother and I were talking the other day about lacrosse photography. We're wondering if any of you would be interested in a class talking about the ins and outs of getting great shots at lacrosse games. If you or someone you know (like a team photographer) would have any interest, please reply to this email and let me know. You can see his photos here and mine. We've shot youth, high school, MCLA, WCLA, NCAA, Pro and even International lacrosse. Speaking of photos, if you have any old photos of lacrosse in Utah, I'm collecting them for use on social media and prints for anyone who may want them. Send me an email with what you have! ClinicsThere are a couple of great clinics coming up. On Saturday, February 27, Tornadic is hosting a camp/7s games for girls 4th-8th graders. Learn more here. Also on Saturday, True Lacrosse is offering a FREE Spring Starter Tune Up at Corner Canyon High School. High School ages will be from 9:00 a.m. to 10:30 a.m. with the youth starting at 10:30 a.m. Register here.LaxnumbersFor the older lacrosse fans, Laxnumbers is the reincarnated LaxPower. For the newer lacrosse fans, Laxnumbers is reincarnating LaxPower, which was an old lacrosse website that housed lacrosse schedules, news, forums, etc. LaxPower was a staple in any lacrosse fan/player/coach/ref daily life. They also had an RPI/Power rating before it was cool. I vividly remember checking scores, standings and power rankings in 2000. You can view it here.Utah Lacrosse Fandom SurveyI'll leave the survey open for another few days. If you haven't filled it out yet, please do so! You can find the survey here. I'm excited to share the results with you in the coming weeks. I think that's it for this week. If you've made it this far, thank you! Next week we should have our first coaches poll which I'm very excited about. Please forward this to a friend who also loves lacrosse. — Tim Haslam This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.utahlaxreport.com

Good morning lax fans! I hope you're doing well and staying safe. Let's jump right into the action. UVU Head Coach Brian BarnhillMy latest podcast (available on Apple Podcasts and Spotify or listen above) features Utah Valley Head Coach Brian Barnhill. I first met Barnhill at Alta when his son Mason was a close defenseman who then went on to Corner Canyon. I've always loved to talk to Barnhill about lacrosse because he brings a fresh perspective and is very humble. We talk about how he became the coach at UVU, what the Wolverines have been up to, the culture at UVU, favorite lacrosse memories (hint: it involves an upset of a No. 1 ranked team) and more. Wasatch Invitational This weekend was a busy one! The Wasatch Invitational was in full swing at Galena Park. The Boys HS Elite division featured 17 teams and the Boys HS Open division had 10 teams from Utah, Colorado, Arizona, Wyoming, California, Montana and Washington. NCAA, NJCAA and MCLA coaches from as far as Florida were also on hand to view the talent assembled. In the Elite bracket, 212 Lacrosse went undefeated en route to a 6-5 win over OC Crush. The True Utah 2024 team were the Open division champions after beating Colorado Chill, 7-5. “This years Wasatch Invitational was a huge success and the growth has been exponential,” said Danny Larkin, who with his brother Ricky, host the event. “Bringing high level club teams from all over the West and top college coaches from across the entire country to Utah is our goal with the Wasatch Invitational. The college coaches were very impressed with the level of play in Utah.”“It was really amazing to see teams coming from multiple states for this high school only event that brought out twelve plus different college programs,” said Ricky Larkin. “The overall level of competition was solid in both divisions. College coaches all were very impressed with the talent out here, and that's what these players from the West need: more exposure.”Follow Wasatch LC on Instagram to see the All-Tournament team when it's released. Aloha TournamentThe Aloha Tournament also took place this weekend. At the girls high school level, Force Elite won the event with a 3-0-1 record which is no surprise after seeing ball movement like this and a sweet BTB finish. In the Boys High School division, ADVNC San Fransisco 2022 took first with a 4-0 record. News & NotesCan we talk about a game-changing moment for Westminster Men's & Women's programs? Let there be light! Yes, that's right, we'll finally be able to enjoy a night game at Dumke Stadium. Also, don't forget to check out the girls Super 7s. They have a couple more weeks left with championships on October 20/21. Side note: I've been to my share of cold lacrosse games, but the Super 7s Championship I went to in 2014 or maybe 2015 was the coldest I have ever been, but don't let that sway you. Go check out the games! I also had the opportunity to take pictures of the Farmington v. Bingham scrimmage on Saturday. You can view the full gallery here. My last thought comes from an experience I had about a week ago. I had listed a fly-fishing net on Facebook Marketplace and a person had inquired about it. We went back and forth, trying to find a good time and eventually did. I got out of my car and he was wearing a Johns Hopkins lacrosse jacket. I asked if he had played at Hopkins and he had. He is living locally and teleworking. We later exchanged emails and he's on his way to becoming part of OUR community. The worldwide lacrosse community is special. The national lacrosse community is unlike any other sport. And our local community is outstanding, but we can be better. While many who have been involved in the sport may say we are huge and we are sanctioned, we must not rest on one's laurels! We need to continue to be welcoming and inclusive, no matter what. To those who are new to the sport, please ask questions! My story also serves as a great reminder to treat everyone with respect no matter what. You never know if the person that gets out of the other car will have a Hopkins, or insert school name, lacrosse jacket on. Don't forget, please send any questions or comments to tim@timhaslam.com. Don't be a jerk to refs and thanks again for reading. If you've made it this far, please forward to a lacrosse loving friend. - Tim Haslam This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.utahlaxreport.com

Straight from the Goal Mouth is co-hosted by former Wagner College teammates Andrew Daly, head men's lacrosse coach at Wells College, and Ian Gallagher, associated head coach of men's lacrosse at the University of Mary Washington. Episode one features Jason King, head coach at University of St. Thomas along with the two former head coaches at St. Thomas - Brian Gross and Pete Moosbrugger. The conversation centers around the differences between MCLA and NCAA programs, how to handle the pressure of wearing a target on your back and what youth coaches can do to get kids more prepared to play at the college level and more.

It's Episode 3 of the Podcast and Taylor Redd is back to discuss all the happenings in the MCLA this past week. Jordan and Taylor recap some of the most impactful games from the past week and delve into why teams have been struggling clearing the ball this year (and if you are a coach, what to do about it). Here's what we cover: 0:44 – The week in review 1:14 – Grand Canyon upsets Concordia 8:15 –Chapman surges in the second half to put away Cal Poly 10:32 - South Carolina beats BYU, BYU beats Arizona 16:00 - Virginia Tech's California swing. 19:58 - Georgia Tech takes down undefeated Buffalo, Colorado State escapes Northeastern in the last second 20:56 - What did we learn from the week? 21:41 - Why are teams struggling so much to clear effectively? 31:04 - Rank 'Em - Cal, GT, Liberty 38:44 - How far does Concordia fall? 41:47 - How far should Michigan State fall? --- Support this podcast: https://anchor.fm/vvlacrosse/support

Welcome to the first Virtually Varsity Podcast! Get caught up with the latest from the last week of MCLA action. What's inside: 4:30 - The infamous wave video and if it's a big deal 10:40 - What teams had the best weekend? 17:10 - What teams had the worst weekend? 21:15 - Who was the hardest team to rank this week? 27:55 - MCLA Rankings 1-20, a slew of other teams to consider View the rankings at VirtuallyVarsity.com --- Support this podcast: https://anchor.fm/vvlacrosse/support

Today, Tom has a conversation with Dr. Susan Bell, Superintendent of Windsor Locks Public Schools, a Connecticut district moving to mastery-based learning where students show what they know and progress when they demonstrate mastery.   Next month, after 17 years working with Windsor Locks, Dr. Bell will be joining the Mastery Transcript Consortium. There she will be helping schools and districts adopt new competency-based transcripts that help learners better communicate their capabilities and accomplishments.   In this episode, they discuss Windsor Locks's goals and efforts to becoming a mastery-based district, Susan's work at Windsor Locks and the strides she has made in her 17 years as Superintendent, and all about her new position at Mastery Transcript Consortium and the work she hopes to accomplish there.   Key Takeaways: [:15] About today's conversation with Dr. Susan Bell. [:50] About the community of Windsor Locks in Connecticut. [2:59] About Susie's early life and education. [3:40] Did Susie go to MCLA with the intentions of becoming a teacher? [4:23] Susie's start as a counselor at Windsor Locks, in 2001. [5:29] What did Susie study at the University of Hartford? [6:17] The importance of building a rich path to principalship. [7:52] About Windsor Locks's goals and how they were formed. [10:00] Windsor Locks's graduate profile. [11:09] Windsor Locks's efforts to become a mastery-based district and where the idea originated. [13:53] The challenge of becoming more competency-based and student-centered. [16:07] Did Dr. Susan Bell start in K-8? [17:20] How Susie's work has helped her reimagine high school. [21:09] Supporters that have helped Windsor Locks. [25:15] The progress being made through Susie's hard work. [27:11] Susie's new position at Mastery Transcript Consortium. [29:05] Why a new transcript and the work at MTC is so important.   Mentioned in This Episode: Windsor Locks Public Schools Mastery Transcript Consortium Massachusetts College of Liberal Arts University of Hartford Great Schools Partnership Hartford Foundation for Public Giving Connecticut Center for School Change Nellie Mae Education Foundation High Tech High Most Likely to Succeed film   Want to Learn More About Another Fantastic Connecticut Superintendent? Listen to: “S3: E16 Leading A Student-Centered Agenda: 10 Lessons from Mark Benigni”   Get Involved: Check out the blog at GettingSmart.com. Find the Getting Smart Podcast on iTunes, leave a review and subscribe.   Is There Somebody You've Been Wanting to Learn From or a Topic You'd Like Covered? To get in contact: Email Jessica@GettingSmart.com, Tweet @Getting_Smart, or leave a review. The Getting Smart team will be sure to add them to their list!